Table 3 Associations between the clinical and laboratory characteristics of the patients and SMFS in univariate and multivariate logistic regression analysis

Age (≥ 45 vs. < 45 years)

1.008–1.647

Gender (Male vs. Female)

0.635–1.184

Smoking Status (Present vs. Absent)

0.871–1.440

Drinking Status (Present vs. Absent)

0.615–1.349

Family history (Present vs. Absent)

0.627–1.010

Calcium, mmol/L (≥ 2.4 vs. < 2.4)

0.725–1.186

Phosphorus, mmol/L (≥ 1.15 vs. < 1.15)

0.725–1.185

Magnesium, mmol/L (≥ 0.93 vs. < 0.93)

0.552–1.172

CRP, mg/L (≥ 1.91 vs. < 1.91)

1.618–2.706

1.108–1.897

WBCs, ×10⁹ (≥ 6.9 vs. < 6.9)

0.822–1.342

Neutrophils, ×10⁹ (≥ 4.2 vs. < 4.2)

0.921–1.504

HGB, g/L (≥ 145 vs. < 145)

0.653–1.068

Platelets, ×10⁹ (≥ 229 vs. < 229)

0.887–1.449

ALT, U/L (≥ 22.2 vs. < 22.2)

0.760–1.241

AST, U/L (≥ 21 vs. < 21)

1.003–1.641

ALP, U/L (≥ 70 vs. < 70)

1.570–2.606

1.275–2.145

LDH, U/L (≥ 172.2 vs. < 172.2)

1.514–2.514

1.098–1.847

ALB, g/L (≥ 44.9 vs. < 44.9)

0.542–0.889

GLB, g/L (≥ 30.5 vs. < 30.5)

1.242–2.047

Cholesterol, mmol/L (≥ 5.12 vs. < 5.12)

0.747–1.220

T lymphocytes, ×10⁹ (≥ 1.8 vs. < 1.8)

0.714–1.167

Monocytes, ×10⁹ (≥ 0.4 vs. < 0.4)

1.118–1.832

Pathology (Differentiated vs. Undifferentiated

0.153–1.101

Cranial nerve injury (Absent vs. Present)

0.666–1.736

EBV-DNA, copies/ml

  < 1000

1.000

1.000

 1000–9999

1.349–2.832

1.045–2.215

 10,000–99,999

1.959–3.881

1.277–2.601

 100,000–999,999

3.147–6.631

1.829–4.004

  ≥ 1,000,000

4.221–13.151

1.829–8.533

Treatment method

 Radiotherapy

1.000

 CCRT

0.639–1.773

 Neo + Radiotherapy

0.834–2.521

 Neo + CCRT

0.426–1.325

Radiotherapy technology (IMRT + 3DCRT vs. CRT)

0.378–1.471

T category

 1

1.000

 2

1.269–8.020

 3

1.538–9.157

 4

1.596–9.856

N category

 0

1.000

1.000

 1

0.928–3.230

0.765–2.681

 2

1.638–5.558

1.156–3.995

 3

3.281–10.925

1.947–6.704

 4

3.079–12.933

1.742–7.559